



INTRAOP

**Media Contact:**

Regina Nisita

Affect Strategies

212.398.9680 x145

[regina@effectstrategies.com](mailto:regina@effectstrategies.com)

**The Mobetron Makes Groundbreaking Radiation Therapy Technique a Reality for Japanese Breast Cancer Patients**

*Nagoya University Hospital joins the European Institute of Oncology in making single-dose intraoperative electron-beam radiation therapy (IOERT) a key part of their breast cancer treatment protocol*

**Sunnyvale, California; March 10, 2008:** IntraOp Medical Corporation (OTCBB: IOPM), announced today that doctors at Nagoya University Hospital in Nagoya, Japan, are now using the Mobetron to deliver intraoperative electron-beam radiation therapy (IOERT) to breast cancer patients. The Mobetron allows Nagoya University Hospital to employ the groundbreaking single-dose technique, a treatment that offers substantial physiological and psychological benefits to breast cancer patients.

Nagoya University Hospital acquired the Mobetron, IntraOp Medical's mobile, self-shielding linear accelerator, in October, 2006. Nagoya University has had a long and distinguished history of using IOERT through patient transportation, particularly for the treatment of pancreatic cancer. They are the first hospital in Japan to provide IOERT in a standard operating room. Led by Chairman and Professor of Surgery, Dr. Akimasa Nakao, Nagoya University Hospital doctors have not only continued to use the Mobetron to treat pancreatic cancer, but they are also pioneering the use of IOERT for their breast cancer patients.

The European Institute of Oncology in Milan, Italy, has been a vocal proponent of IOERT for many years. Renowned breast surgeon Dr. Umberto Veronesi, Director of the European Institute of Oncology, developed what is known as the single-dose approach for treating breast cancer. Inspired by Dr. Veronesi's record of positive outcomes, Nagoya University Hospital adopted his single-dose technique. Since December, 2007, Nagoya University Hospital has been using the Mobetron to administer IOERT to breast cancer treatments.

The term "single-dose" refers to IOERT's ability to eliminate the need for post-surgery radiation therapy. The Mobetron allows Nagoya University Hospital doctors to deliver a single dose of radiation to patients during their cancer surgery. By delivering radiation at the time that the cancerous tissue is excised, the Mobetron administers in one treatment the equivalent of six weeks of post-operative radiation therapy.

The benefits of using the Mobetron to deliver single-dose radiation therapy are numerous. When the Mobetron delivers single-dose IOERT, it allows radiation and surgical oncologists to visually see the exact area they need to radiate and immediately deliver high doses directly to the affected tissue when any residual tumor cells will be most vulnerable. It is more convenient for the patient since all of the radiation that is needed to control the disease is given at the same time as surgery. Single-dose IOERT also results in substantially less dose to the healthy tissues and there is complete sparing of radiation to the skin which should lead to better cosmetic results.

In addition to maximizing positive outcomes, using the Mobetron to deliver single-dose radiation therapy greatly reduces the overall treatment time for the patient, resulting in a faster recovery and return to daily life. It also increases the chances for oncoplastic reconstruction at the time of the lumpectomy, making breast reconstruction a real alternative to mastectomy for many breast cancer patients.

“The doctors at the Nagoya University Hospital are delighted to be able to offer single-dose IOERT to their patients,” says Jay Bhatt, Senior Advisor to IntraOp Medical Corporation. “Nagoya University has long been a leader in providing innovative approaches to cancer treatment. With the Mobetron and single-dose IOERT, they are able to continue this tradition. I am convinced that their approach will result in breast preservation for their patients with more convenience at less cost.”

### **About IntraOp**

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

For more information about IntraOp Medical and the Mobetron, please visit:

[www.intraopmedical.com](http://www.intraopmedical.com)

For more information about Nagoya University, please visit: [www.nagoya-u.ac.jp/](http://www.nagoya-u.ac.jp/)

### **Forward-looking Statements**

*This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.*

